Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Orchid Pharma Launches New Division to Tackle Antimicrobial Resistance in India
Orchid AMS will work with 2,500 to 3,000 hospitals over the next two to three years to implement antimicrobial stewardship programs (AMSPs).
- By PharmaNews Live Desk
- New Delhi
- Sep 17, 2024
Chennai-based Orchid Pharma has announced the launch of Orchid AMS (Antimicrobial Solutions), a division focused on addressing the growing threat of Antimicrobial Resistance (AMR) in India. The new initiative aims to combat AMR through innovative products, support programs, and digital solutions. Orchid AMS will work with 2,500 to 3,000 hospitals over the next two to three years to implement antimicrobial stewardship programs (AMSPs). These programs are designed to strengthen hospitals’ ability to combat infections through responsible antibiotic use and real-time data on pathogen resistance patterns.
The company has outlined a five-pronged approach to AMR, which includes launching advanced products such as Orblicef™ (Cefepime Enmetazobactam), Ceftaroline, and Cefiderocol, expanding its product portfolio to support a wide range of hospitals, and offering digital solutions that provide healthcare professionals with real-time data.
Additionally, Orchid AMS will promote responsible antibiotic use through its “First Do No Harm” team, which will provide unbiased, evidence-based recommendations. Orchid Pharma is organizing a series of sessions aimed at healthcare professionals, policymakers, and industry experts to discuss the role of antimicrobial stewardship and AMR. These sessions will take place in cities including Delhi, Mumbai, Bangalore, Chennai, and Hyderabad.
Orchid Pharma’s Managing Director, Manish Dhanuka, said, “The launch of Orchid AMS demonstrates our commitment to addressing the public health threat posed by AMR. With our expertise in antimicrobials and USFDA-approved manufacturing, we aim to make a significant impact.”
Rajnish Rohatgi, CEO of Orchid AMS, added, “AMR is a complex issue requiring a multi-faceted approach. We commit to responsible antibiotic promotion and invite other pharmaceutical companies to collaborate with us to tackle this challenge.”
The launch comes at a critical time as India faces a significant AMR burden, with over one million deaths attributed to AMR in 2019. According to the company's statement, Orchid AMS’s efforts align with India’s National Action Plan on AMR, which focuses on prevention, access to quality treatment, and the promotion of innovation.